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ABSTRACT 
 
MicroRNAs (miRNAs) are small RNA molecules that modulate gene expression through degradation of 
specific mRNAs and/or repression of their translation. miRNAs are involved in both physiological and 
pathological processes, such as apoptosis and cancer. Their presence has been demonstrated in several 
organisms as well as in viruses. Virus encoded miRNAs can act as viral gene expression regulators, but they 
may also interfere with the expression of host genes. Viral miRNAs may control host cell proliferation by 
targeting cell-cycle and apoptosis regulators. Therefore, they could be involved in cancer pathogenesis. 
Computational prediction of miRNA/target pairs is a fundamental step in these studies. Here, we describe the 
use of miRiam, a novel program based on both thermodynamics features and empirical constraints, to predict 
viral miRNAs/human targets interactions. miRiam exploits target mRNA secondary structure accessibility 
and interaction rules, inferred from validated miRNA/mRNA pairs. A set of genes involved in apoptosis and 
cell-cycle regulation was identified as target for our studies. This choice was supported by the knowledge 
that DNA tumor viruses interfere with the above processes in humans. miRNAs were selected from two 
cancer-related viruses, Epstein-Barr Virus (EBV) and Kaposi-Sarcoma-Associated Herpes Virus (KSHV). 
Results show that several transcripts possess potential binding sites for these miRNAs. This work has 
produced a set of plausible hypotheses of involvement of v-miRNAs and human apoptosis genes in cancer 
development. Our results suggest that during viral infection, besides the protein-based host regulation 
mechanism, a post-transcriptional level interference may exist. miRiam is freely available for downloading at 
http://ferrolab.dmi.unict.it/miriam. 
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INTRODUCTION 
 
MicroRNAs (miRNAs) are small non-coding RNAs 
involved in post-transcriptional gene silencing (PTGS) that 
is a highly-conserved mechanism for regulating gene 
expression. miRNAs inhibit protein synthesis by binding 
with the 3’UTR or, rarely, the coding sequence of specific 
mRNAs (Bartel, 2004). 
 
miRNAs are known to be involved in several physiological 
processes, such as apoptosis, development and cell 
differentiation, and their aberrant expression is observed in 380 
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several diseases such as cancer, neurodegeneration and 
cardiac pathologies (Garofalo et al, 2008). 
 
miRNAs are also expressed by viruses (v-miRNAs), which 
may act as self-regulators. It has been shown that the 
EBV-encoded miRNA, miR-BART2, down-regulates the 
viral DNA polymerase BALF5, thus inhibiting transition 
from latent to lytic viral replication (Barth et al, 2008). v-
miRNAs can also interference with the host cell transcripts 
(Cullen, 2006). The cellular protein p53, an up-regulated 
modulator of apoptosis (PUMA), is regulated by the EBV-
encoded miR-BART5. The expression of miR-BART5 
renders infected miR-BART5-expressing cells less 
sensitive to pro-apoptotic agents, but apoptosis can be 
triggered by depleting miR-BART5 or inducing the 
expression of PUMA. This shows the capability of v-
miRNAs to facilitate the establishment of latent infection 
by promoting host cell survival (Choy et al, 2008). 
 
The silencing of some nodes of the apoptotic pathway 
would give to the virus an important advantage during its 
lysogenic phase, since the host cells would not die by cell 
death triggered from infection and the virus could 
complete its vital cycle. Many v-miRNAs are located in 
proximity or inside viral latency genes and, presumably, 
co-transcribed with them (Nair and Zavolan, 2006). On the 
other hand, in many cases of viral infection the activation 
of apoptosis is needed during the lytic cycle of the virus 
allowing the processing of capsides and viral particles 
dissemination (Mendez et al, 2004). 
 
The negative and positive modulation of the apoptotic 
process is a fundamental activity for beginning and 
concluding the vital cycle of the virus. The above 
mentioned cases and other recent findings show that, 
besides well-known protein mechanisms of apoptosis 
control by viruses, there are other strategies of apoptosis 
regulation based on translational repression by miRNAs 
(Klase et al, 2009). 
 
Apoptosis may also represent one of the most important 
links between viral infections and oncogenesis. All tumor 
related viruses seem to share the same approach to 
interfere with apoptosis and cell-cycle genes (Damania, 
2007). Thus, they may directly promote neoplastic 
transformation of infected cells or facilitate cancer 
insurgence in favourable contexts. For example, the 
Kaposi Sarcoma Herpes Virus encodes a protein called 
LANA, which inhibits the tumor suppressor protein p53, 
thus promoting cell survival, virus latency and 
oncogenesis (Si and Robertson, 2006). 
 
In this article we present computational predictions of 
human targets for v-miRNAs encoded by two tumor 
related viruses, Epstein-Barr Virus (EBV) and Kaposi 
Sarcoma Herpes Virus (KSHV). The predictions are 
computed by a novel approach, which combines 
thermodynamics and empirical constraints in order to 
produce reliable miRNA/target duplexes.  
 
Our results demonstrate v-miRNA/human target pairs 
which possess good binding scores, some of which are 
also supported by publicly available data on gene 
expression profiles. These findings are consistent with 
previously reported regulation mechanisms and offer a set 
of candidate targets for further biological validation. 
 
MATERIALS AND METHODS 
 
Computational prediction of v-miRNA/target duplexes 
v-miRNAs/human target interactions were predicted by 
miRiam, a novel tool capable of screening large databases 
of miRNAs in order to identify the most probable binding 
sites on a given mRNA, in a reasonable time. miRiam is 
based on a combined approach which makes use of 
thermodynamics and pairing constraints inferred from 
known miRNA/target pairs. 
 
The importance of target secondary structure in miRNA- 
based silencing has been previously demonstrated (Robins 
et al, 2005). Target binding sites must be accessible and 
interactions with miRNAs have to be energetically 
favourable (Kertesz et al, 2007). Moreover, to predict 
duplexes reliably several features inferred from known 
miRNA/mRNA pairs need to be taken into account. For 
example, miRNA 5’end contains the seed region, which is 
important in their binding with the target using near 
perfect complementarity. Nevertheless, the seed region 
may sometimes contain G:U wobbles, and the number of 
G:U wobbles in this region appears to be inversely related 
to silencing efficacy of the miRNA. Almost all known 
miRNA binding sites are located in the 3’ UTRs of target 
mRNAs, and multiple binding sites have been observed in 
several cases, potentially increasing the efficacy of 
silencing (Grimson et al, 2007). 
 
Given a target mRNA sequence and a database of 
miRNAs, which can be retrieved from miRBase, miRiam 
performs the following steps: 
 
i) Target accessibility evaluation: Base pairing 
probabilities of the target are computed by Vienna RNA 
package functions (Hofacker et al, 1994) and used to 
identify accessible regions, i.e. less paired sub-sequences.  
 
ii) Alignment of miRNA/binding sites: The complementary 
base-pair alignment of accessible sub-sequences with 
miRNAs is then computed. A variant of the classical 
Needleman-Wunsch pairwise sequence alignment in 
which only matches of complementary base pairs are 
allowed is used. 
 
iii) Post alignment filtering: All duplexes which do not 
satisfy previously described empirical sequence 
constraints are discarded. The remaining pairs are 
presented to the user ordered by their binding energies. 
 
miRNAs and targets selection 
EBV and KSHV miRNAs were obtained from miRBase 
(Griffiths-Jones et al, 2008). Target mRNA transcripts 
were downloaded from GenBank, chosen based on their 
Gene Ontology annotations. Genes annotated with the 
following terms were selected: Pro-apoptosis, cell cycle 
arrest, cell cycle checkpoint, negative regulation of cell 
cycle, negative regulation of cyclin-dependent kinase 
activity, and negative regulation of mitotic cell cycle. 381 
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Expression data 
The expression profiles of the predicted targets were 
retrieved from the NCBI GEO Profiles database. Among 
the available datasets, NCBI GDS940 and GDS989 were 
selected as they were obtained from suitable biological 
specimens (infected cells and corresponding uninfected 
controls). For each predicted target, experiments 
performed on EBV and KSHV infected cells were 
selected and the ratios between the mean gene expression 
values in the infected and in the control samples were 
computed. The evaluation of fold change significance 
using formal statistical methods was not possible due to 
the small number of available samples. For this reason 
the observed ratios should be considered as qualitative 
descriptors supporting or confuting the proposed 
hypotheses. The data on the v-miRNA expressing tissues 
were obtained from the literature (Pfeffer et al, 2004; 
Pfeffer et al, 2005; Cai and Cullen, 2006; Cai et al, 2006; 
Kim et al, 2007; Marshall et al, 2007; Zhu et al, 2009)  
and from the miR-Z database (Hausser et al, 2009). 
 
RESULTS 
 
Representative results of our predictions are shown in 
Tables 1 and 2. Table 1 contains the EBV miRNAs 
predicted targets while Table 2 shows the predictions for 
KSHV miRNAs. For each v-miRNA, the tissues where it 
is expressed, the predicted human targets and. Only the 
transcripts with perfect matches with the seed of v-
miRNAs in structurally-accessible regions were selected 
(maximum one G:U wobble allowed in the seed region). 
These results indicate the putative capability of EBV 
and KSHV to interfere with the expression of host genes 
involved in apoptosis and cell cycle regulation. 
Moreover, some of the predictions are supported by 
gene expression profiles in EBV and KSHV infected 
cells. 
 
Table 3 shows, for each predicted target, the ratios 
between the mean expression values in the infected and 
control cells. A value less than 1 indicates that the gene 
is under-expressed in the infected samples, compared to 
the control cells. Only these values are reported, since 
they are the significant ones concerning our analysis. 
The complete data are given in supplementary tables 
(Tables S1-S3). 
 
Finally, in order to assess the reliability of the proposed 
method, we performed a comparison between miRiam and 
some of the most popular available tools for miRNA target 
 
 
Table 1. Predicted targets for EBV v-miRNAs. For each miRNA, the list of tissues where it is expressed, the predicted targets, the 
number of site on each target transcript and the associated ontological term are given. Tissues legend: AML: Acute myeloid leukemia, 
BCLL: B-Chronic lymphocytic leukemia, BL: Burkitt’s lymphoma, ESC: Embryonic stem cells, GC: Gastric carcinoma, HD: Hodgkin’s 
disease, L: Lymphoblasts, LAC: Lung’s adenocarcinoma, LBCL: Large B-cell lymphoma, LU: Lung, MCL: Mantle cell lymphoma, M: 
Myeloblasts, NC: Nasopharyngeal carcinoma, PEL: Primary-effusion lymphoma, USSC: Unrestricted somatic stem cells. 
 
v-miRNA  Tissues  Target  Sites  Target’s GO terms 
miR-BART3-3p  BCLL, BL, HG, L, LBCL, MCL  CASP10  1  Pro-Apoptosis 
miR-BART6-3p   BCLL, BL, HG, L, LBCL, MCL, 
NC 
BAD 1  Pro-Apoptosis 
miR-BART7  AML, BCLL, BL, ESC, GC, HG, 
LBCL, MCL, USSC 
RB1  1  Negative regulation of cell cycle 
miR-BART9  BCLL, BL, HG, MCL  RAD1  2  Cell cycle checkpoint 
RB1  1  Negative regulation of cell cycle 
miR-BART10  BCLL, BL, GC, HG, MCL  ZAK  1  Cell cycle arrest 
miR-BART11-5p  BCLL, BL, HG, L, NC  CASP3  1  Pro-Apoptosis 
miR-BART11-3p   BCLL, BL, HG, L, MCL, NC  TP53  1  Regulation of cell cycle 
miR-BART12  BCLL, BL, GC, NC, PEL  TP53  1  Regulation of cell cycle 
miR-BART13  BCLL, BL, HG, L, MCL CASP3  1  Pro-Apoptosis 
APC  2  Negative Regulation of cyclin-
dependent kinase activity 
miR-BART15  BCLL, BL, HG, MCL  CASP3  1  Pro-Apoptosis 
miR-BART16   BCLL, BL, HG, L, MCL  BID  1  Pro-Apoptosis 
miR-BART19  BL, HG, MCL  APBB2  2  Cell cycle arrest 
ZAK  1  Cell cycle arrest 
STK4 2  Pro-Apoptosis 
miR-BART20-3p   BCLL, BL, L  BAX  1  Pro-Apoptosis 
miR-BHRF1-1  BCLL, BL, HG, L, MCL  CUL4  2  Cell cycle arrest 
miR-BHRF1-2  AML, BCLL, BL, ESC, HG, L, 
LBCL, M, MCL, LAC, LU, 
USSC 
RAD1  1  Cell cycle checkpoint 
miR-BHRF1-2*  -  CCNG2  1  Cell cycle checkpoint 
GAS1  2  Cell cycle arrest 
RB1  2  Negative regulation of cell cycle 
miR-BHRF1-3   BCLL, BL, HG, L, LBCL, MCL  BID  1  Pro-Apoptosis 382 
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Table 2. Predicted targets for KSHV v-miRNAs. For each miRNA, the list of tissues where it is expressed, the predicted targets, the 
number of site on each target’s transcript and the GO term associated to the targets are shown. Tissues legend: BCBL: Body cavity-
based lymphoma, BL: Burkitt’s lymphoma, PEL: Primary-effusion lymphoma. 
 
v-miRNA  Tissues  Target  Sites  Target’s GO terms 
miR-K12-1  BCBL, BL, PEL  RBL1  1  Negative regulation of cell cycle 
RAD1  1  Cell cycle checkpoint 
miR-K12-2  BCBL, BL, PEL  CASP10  1  Pro-Apoptosis 
APC  2  Negative Regulation of cyclin-
dependent kinase activity 
RAD1  1  Cell cycle checkpoint 
miR-K12-3  BCBL, BL, PEL  APC  1  Negative Regulation of cyclin-
dependent kinase activity 
STK4 3  Pro-Apoptosis 
miR-K12-4-5p  BCBL, BL, PEL  RBL1  1  Negative regulation of cell cycle 
ZAK  1  Cell cycle arrest 
miR-K12-6-3p  BCBL, BL, PEL  BID  1  Pro-Apoptosis 
BTG3  1  Negative Regulation of mitotic 
cell cycle 
miR-K12-9*  BCBL, BL, PEL  CASP8  1  Pro-Apoptosis 
TP53  1  Regulation of cell cycle 
miR-K12-10a  BCBL, BL, PEL  CASP10 1  Pro-Apoptosis 
miR-K12-11  BL  RB1  1  Negative regulation of cell cycle 
RBL1  1  Negative regulation of cell cycle 
APC  3  Negative Regulation of cyclin-
dependent kinase activity 
miR-K12-12 PEL  CASP10  1  Pro-Apoptosis 
 
 
 
Table 3. Expression profiles of the predicted targets in infected cells. The profiles were retrieved from the NCBI GEO Profiles 
database. For each target, the GEO record ID, the virus, the mean value in the control sample (not infected), the mean value in the 
infected cell and the infected/control ratio are shown. Only values less than 1 are reported, since they indicate that the gene is under-
expressed in the infected sample, compared to the control cell. 
 
Gene  GEO Record  Virus  Mean (Control)  Mean (Infected)  Ratio (I/C) 
ABL1  GDS989 - 1636_g_at   EBV  5928.75  3531.80  0.59 
GDS989 - 39730_at   EBV  5839.95  3504.20  0.60 
GDS989 - 1635_at  EBV  2786.60  1428.30  0.51 
GDS940 - 202123_s_at   KSHV  406.35  246.35  0,60 
APC  GDS940 - 203525_s_at   KSHV  110.60  63.90  0.57 
BID  GDS940 - 204493_at   KSHV  263.25  140.40  0.53 
BTG3  GDS940 - 213134_x_at  KSHV 471.05  233.25  0.49 
CCNG2  GDS989 - 1913_at  EBV  2690.40  1679.80  0.62 
  GDS940 - 211559_s_at  KSHV  109.65  98.55  0.89 
RAD1  GDS989 - 36857_at   EBV  2365.45  1954.6  0.82 
GDS940 - 204461_x_at   KSHV  176.50  77.55  0.43 
GDS940 - 204460_s_at  KSHV  136.75  73.85  0.54 
GDS940 - 210216_x_at  KSHV  158.55  102.85  0.64 
RB1  GDS989 - 2044_s_at  EBV  1307.35  1149.60  0.87 
GDS940 - 203132_at  KSHV  157.80  140.90  0.89 
SMAD3  GDS940 - 205398_s_at   KSHV  314.75  157.80  0.50 
STK4  GDS940 - 211085_s_at  KSHV  19.65  12.10  0.61 
TP53  GDS989 - 1974_s_at  EBV  1712.40  1561.70  0.91 
GDS989 - 1974_s_at  KSHV  1712.40  1530.25  0.89 
GDS940 - 201746_s_at  KSHV  405.70  370.00  0.91 
ZAK  GDS940 - 218833_at   KSHV  42.50  30.25  0.71 
 
 
prediction: RNA Hybrid, miRanda, RNA22 and PITA 
(Rehmsmeier et al, 2004; John et al, 2005; Huynh et al, 
2006). For this purpose, we chose a set of validated v-
miRNA/human targets for which binding sites details were 
available. Results are reported on Table 4. They show the 
capability of miRiam to identify all the validated binding 
sites, in most cases as top ranking. We evaluated the 
statistical significance of our results by the Friedman rank 
test. While miRiam is comparable to PITA, in terms of 
number of correct sites identified, it outperforms the other 
tools in terms of the number of correct binding sites and 
their ranking. 383 
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Table 4. Comparison of miRiam to other target prediction tools. We chose a set of validated v-miRNA/human targets for which 
binding sites details were available. For each tested tool, the ranking of the site in the output is reported. A “-“ symbol indicates that 
the tool wasn’t able to identify the site. P-values are computed by using the Friedman Rank Test, to assess whether or not miRiam 
significantly tends to perform better than the other tools across experimentally validated targets. Results show that miRiam performs 
better than RNA Hybrid, miRanda and RNA22, while is comparable to PITA. 
 
Virus mIRNA  Target  Transcript  Site 
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KSHV miR-K12-11  BACH-1  NM_001186.2  3156-3162  2 2 -  -  3
KSHV miR-K12-11  BACH-1  NM_001186.2  4504-4511  3 - -  -  2
KSHV miR-K12-11  BACH-1  NM_001186.2  4565-4571  1 - -  -  1
KSHV miR-K12-11  BACH-1  NM_001186.2  4714-4720  4 - -  -  7
KSHV miR-K12-11  BACH-1  NM_206866.1  3284-3290  2 3 -  -  3
KSHV miR-K12-11  BACH-1  NM_206866.1  4632-4639  3 - -  -  2
KSHV miR-K12-11  BACH-1  NM_206866.1  4693-4699  1 - -  -  1
KSHV miR-K12-11  BACH-1  NM_206866.1  4842-4848  4 - -  -  7
HCMV miR-UL112-1  MICB  NM_005931.3  1319-1323  16* 1 2  -  -
EBV miR-BART5  BBC3  NM_001127240.1 1366-1372  1 1 1  -  1
EBV miR-BART5  BBC3  NM_001127241.1 1147-1153  1* 1 1  -  1
EBV miR-BART5  BBC3  NM_001127242.1 956-962  1* 1 1  -  1
EBV  miR-BART5  BBC3  NM_014417.3     1450-1456  1 1 1  -  1
KSHV miR-K5  BCLAF1  NM_014739.2  5301-5308  1 10 -  2  3
KSHV miR-K5  BCLAF1  NM_001077440.1  5148-5155  1 9 -  2  3
KSHV miR-K5  BCLAF1  NM_001077441.1  4782-4789  1 10 -  2  3
       p-values  - 0.05 0.03 <  0.0001  0.25
 
*miRiam was able to identify these sites by relaxing the structural accessibility filter.  
 
 
 
DISCUSSION 
 
v-miRNAs vs human targets 
Epstein Barr herpesvirus (EBV) is associated with several 
tumor types, such as Burkitt’s lymphoma, nasopharyngeal 
and gastric carcinoma (Damania, 2007). EBV expresses 
two families of miRNAs, which are located in the BART 
and BHRF1 genes (Pfeffer et al, 2004; Cai et al, 2006). 
The BHRF1 miRNAs are expressed in infected primary 
lymphoma, Burkitt’s lymphoma and lymphoblast cell lines 
during late latency and lytic stages, while BART members 
are always expressed in lymphoblasts in all latent stages. 
miR-BART12 has also been found in infected 
nasopharyngeal and gastric carcinoma cell lines (Kim et 
al, 2007). 
 
Kaposi’s sarcoma-associated herpesvirus (KSHV) is 
associated with several forms of cancer like Kaposi’s 
sarcoma and primary effusion lymphomas (Damania, 
2007). KSHV expresses an array of 13 miRNAs in 
infected primary effusion lymphoma and endothelial cell 
lines (Pfeffer et al, 2005; Marshall et al, 2007).  miR-
BHRF1-3, miR-BART16 in EBV and miR-K12-6-3p in 
KSHV show good matches to BID transcript. Moreover, 
BID mRNA levels decrease after viral infection. The BID 
silencing could cause the partial block of the connection 
between the extrinsic apoptotic pathway and the 
mitochondrial one. BID is a target of proteolytic activity of 
CASP8, which is activated by cell surface death receptors. 
Truncated BID translocates in the mitochondria engaging 
BAX to trigger its pro-apoptotic activity, starting the release 
of the cytochrome c. This is a key event in the formation of 
the apoptosoma complex (cytochrome c, APAF1 and 
CASP9) for the beginning of the intrinsic death pathway. 
Consequently, BID inhibition may lower cell sensitivity to 
external signals and promote resistance to apoptosis. 
Moreover, it has been shown that BHRF, the host gene of 
these miRNAs, encodes a protein which acts downstream of 
BID cleavage and upstream of mitochondrial damage, 
resulting in inhibition of TRAIL-induced apoptosis 
(Kawanishi et al, 2002). This makes plausible a function of 
these miRNAs as repressors of apoptosis. 
 
TP53 is a predicted target for EBV miR-BART11-3p, 
miR-BART12 and KSHV miR-K12-9*. In particular two 
different favorable binding sites for both EBV-
miRBART12 and KSHV-miR-K12-9* have been 
identified in TP53 transcript. We also observed a 
significant decrease in TP53 transcript levels following 
EBV and KSHV infections (see Table 3). The presence of 
multiple binding sites for the same miRNA has been 
observed in several experimentally validated pairs. This 
potentially increases the degree of translational 
suppression. TP53 is an important regulator of cell cycle 
arrest, apoptosis, and cellular senescence and it may be 
activated by various forms of cellular stress, as viral 384 
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infection. Several reports provide evidence of how TP53 is 
involved in antiviral activity and how viruses in their 
infection strategy lead to protein inactivation of TP53 (Si 
and Robertson, 2006; Pampin et al, 2006). That being so, a 
further repression device of TP53 based on RNA 
Interference from viruses looks plausible. Moreover, some 
data suggest that functional TP53 can promote the lytic 
cycle of some viruses. Consequently a repression strategy 
controlled by viral microRNAs could be an efficient and 
inexpensive switch on / off system of TP53 activities. 
 
Our data suggest that Cyclin G2 (CCNG2) could be target 
of miRNAs from both EBV and KSHV. This pro-apoptotic 
protein has been found to be downregulated in many 
different tumours (Choi et al, 2009), and a decrease in its 
activity has been associated with improved proliferation. Its 
key role in cell-cycle and cell plasticity in cancer is 
underlined by the observation that the therapeutic effect of 
rapamicyn is also exerted through the enhancement of its 
transcription rate (Kasukabe et al, 2008). 
 
The ability to interfere with tp53 pathway through the post 
transcriptional regulation of some of its fundamental 
components (tp53, BID, cyclin g2) may constitute a 
mechanism to tightly and efficiently control the host 
survival rate improving replication and diffusion of viral 
progeny. Similarly, other genes involved in apoptosis and 
in the regulation of cell cycle, BAD, BTG3, BAX, RAD1, 
ZAK and RB1, among others, are predicted to be targets of 
EBV and KSHV miRNAs. The repression of these genes 
may help the virus to gain control of the host cells, thus 
favoring the accomplishment of the viral life cycle. 
 
v-miRNAs involvement in cancer 
Viruses are often involved in cancer development. They 
may directly promote cell malignancy or facilitate the 
progression of already established tumors (Damania, 2007). 
While protein based mechanisms of interaction between 
virus and hosts have been widely described, a direct 
involvement of v-miRNAs in cancer is not yet 
demonstrated. However, since experimental evidences show 
the capability of v-miRNAs to perturb host genes 
expression (Barth et al, 2008; Klase et al, 2009), their 
contribution to tumor insurgence is plausible. Moreover, a 
miRNA based host regulation system may represent a faster 
way for viruses to counteract cellular response to infection 
promoting their latency. According to Pfeffer and Voinnet 
(Pfeffer and Voinnet, 2006), v-miRNAs could act as direct 
oncogenes or indirectly promote cancer development and 
diffusion, by supporting external etiologic agents. 
 
The predictions presented in this study are consistent with 
these scenarios. In particular the inhibition of central 
nodes of the apoptotic pathways may lead to loss of cell 
cycle control by the cell itself.  
 
CONCLUSIONS 
 
The aim of this work was to produce a set of plausible 
hypotheses of involvement of v-miRNAs and human 
apoptosis genes in cancer development. In the study, we 
have presented computational predictions of v-miRNAs 
and human targets interactions, and show miRNA/target 
duplexes which were energetically favourable and 
consistent with other experimentally validated pairs. 
Moreover, the target binding sites were characterized by 
high structural-accessibility for interactions with miRNAs. 
Future works will focus on providing experimental 
validations of such estimated interactions. Extension of 
predictions to other reasonable human transcripts, such as 
additional nodes of apoptosis pathway, cell-cycle 
regulators and genes involved in immune response, will be 
performed. 
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Supplementary Table S1. Predicted targets for EBV v-miRNAs. For each miRNA, the list of tissues where it is expressed, the 
predicted targets, the number of site on each target’s transcript and the GO term associated to the targets are shown. Tissues legend: 
AML: Acute myeloid leukemia, BCLL: B-Chronic lymphocytic leukemia, BL: Burkitt’s lymphoma, ESC: Embryonic stem cells, 
GC: Gastric carcinoma, HD: Hodgkin’s disease, L: Lymphoblasts, LAC: Lung’s adenocarcinoma, LBCL: Large B-cell lymphoma, 
LU: Lung, MCL: Mantle cell lymphoma, M: Myeloblasts, NC: Nasopharyngeal carcinoma, PEL: Primary-effusion lymphoma, 
USSC: Unrestricted somatic stem cells. 
 
v-miRNA  Tissues  Target  Sites  Target’s GO terms 
miR-BART1-5p  BCLL, BL, HG, MCL  APC  1  Negative Regulation of cyclin-
dependent kinase activity 
CUL2  1  Cell cycle arrest 
TBRG1  1  Cell cycle arrest 
miR-BART2  BCLL, BL, HG, MCL  CDKN2A  1  Negative Regulation of cyclin-
dependent kinase activity 
CDKN2B  1  Cell cycle arrest 
CUL3 1  Pro-Apoptosis 
miR-BART3-3p  BCLL, BL, HG, L, LBCL, 
MCL 
CASP10 1  Pro-Apoptosis 
miR-BART5  BCLL, BL, HG, MCL  AIFM2  1  Pro-Apoptosis 
DAPK1 1  Pro-Apoptosis 
miR-BART6-5p  BCLL, BL, HG, LBCL, MCL  GAS7  1  Cell cycle arrest 
miR-BART6-3p   BCLL, BL, HG, L, LBCL, 
MCL, NC 
BAD 1  Pro-Apoptosis 
miR-BART7  AML, BCLL, BL, ESC, GC, 
HG, LBCL, MCL, USSC 
CASP6 1  Pro-Apoptosis 
CUL3 1  Pro-Apoptosis 
EIF4G2  1  Cell cycle arrest 
FOXO4  1  Cell cycle arrest 
RB1  1  Negative regulation of cell cycle 
TRAF3 1  Pro-Apoptosis 
miR-BART8-3p  AML, BCLL, BL, HG, LBCL, 
MCL 
APBB2  1  Cell cycle arrest 
EIF4G2  1  Cell cycle arrest 
FEM1B 1  Pro-Apoptosis 
GAS1  1  Cell cycle arrest 
SIPA1  1  Negative regulation of cell cycle 
TP53BP2  1  Negative regulation of cell cycle 
miR-BART9  BCLL, BL, HG, MCL  RAD1  2  Cell cycle checkpoint 
RB1  1  Negative regulation of cell cycle 
APBB2  1  Cell cycle arrest 
STK3 1  Pro-Apoptosis 
miR-BART10  BCLL, BL, GC, HG, MCL  CDKN2C  1  Cell cycle arrest 
CUL5  1  Cell cycle arrest 
ZAK  1  Cell cycle arrest 
miR-BART11-5p  BCLL, BL, HG, L, NC  CASP3  1  Pro-Apoptosis 
CUL2  1  Cell cycle arrest 
miR-BART11-3p   BCLL, BL, HG, L, MCL, NC  TP53  1  Regulation of cell cycle 
miR-BART12  BCLL, BL, GC, NC, PEL  TP53  1  Regulation of cell cycle 
APBB2  1  Cell cycle arrest 
miR-BART13  BCLL, BL, HG, L, MCL  APC  2  Negative Regulation of cyclin-
dependent kinase activity 
CASP3 1  Pro-Apoptosis 
CDKN2B  1  Cell cycle arrest 
MAPK1 1  Pro-Apoptosis 
miR-BART14-3p  BCLL, BL, HG, MCL  ABL1  1  Pro-Apoptosis 
BCL211 1  Pro-Apoptosis 
CDKN2D  1  Cell cycle arrest 
DIABLO1 1  Pro-Apoptosis 
PAWR 1  Pro-Apoptosis 
STK4 1  Pro-Apoptosis 
miR-BART15  BCLL, BL, HG, MCL  CASP3  1  Pro-Apoptosis 
CUL3 1  Pro-Apoptosis 
CUL5  1  Cell cycle arrest 
DAPK1 1  Pro-Apoptosis 
miR-BART16   BCLL, BL, HG, L, MCL  BID  1  Pro-Apoptosis 
CIDEB 1  Pro-Apoptosis ©The Authors | Journal of RNAi and Gene Silencing | May 2010 | Vol 6, No 1 | 379-385 | OPEN ACCESS   
DHCR24  1  Cell cycle arrest 
miR-BART17-3p  BCLL, BL, MCL  BOK  1  Pro-Apoptosis 
TRAF3 1  Pro-Apoptosis 
miR-BART18  BCLL, BL, HG, MCL  APC  1  Negative Regulation of cyclin-
dependent kinase activity 
LTA 1  Pro-Apoptosis 
miR-BART19  BL, HG, MCL  APBB2  2  Cell cycle arrest 
APC  1  Negative Regulation of cyclin-
dependent kinase activity 
BTG4  1  Cell cycle arrest 
CDKN2C  1  Cell cycle arrest 
IFNW1  1  Cell cycle arrest 
MAPK1 1  Pro-Apoptosis 
MPHOSPH1  1  Cell cycle arrest 
NLRP1 1  Pro-Apoptosis 
STK4 2  Pro-Apoptosis 
TNFRSF25 1  Pro-Apoptosis 
ZAK  1  Cell cycle arrest 
miR-BART20-3p   BCLL, BL, L  APC  1  Negative Regulation of cyclin-
dependent kinase activity 
BAX 1  Pro-Apoptosis 
CDKN1B 1  Pro-Apoptosis 
DHCR24  1  Cell cycle arrest 
ERN1  1  Cell cycle arrest 
NDUFA13 1  Pro-Apoptosis 
RUNX3  1  Negative regulation of cell cycle 
miR-BHRF1-1  BCLL, BL, HG, L, MCL  BCL211  1  Pro-Apoptosis 
BIK 1  Pro-Apoptosis 
CUL4A  2  Cell cycle arrest 
EI24 1  Pro-Apoptosis 
LATS2  1  Negative Regulation of cyclin-
dependent kinase activity 
MAPK1 2  Pro-Apoptosis 
TRAF3 1  Pro-Apoptosis 
miR-BHRF1-2  AML, BCLL, BL, ESC, HG, L, 
LBCL, M, MCL, LAC, LU, 
USSC 
CUL1  1  Cell cycle arrest 
RAD1  1  Cell cycle checkpoint 
miR-BHRF1-2*  -  APC  1  Negative Regulation of cyclin-
dependent kinase activity 
BNIP3 1  Pro-Apoptosis 
CCNG2  1  Cell cycle checkpoint 
CUL1  1  Cell cycle arrest 
CUL3 1  Pro-Apoptosis 
DAXX 1  Pro-Apoptosis 
DEDD 1  Pro-Apoptosis 
DIABLO 1 Pro-Apoptosis 
ERN1  1  Cell cycle arrest 
FOXO3A 1  Pro-Apoptosis 
GAS1  2  Cell cycle arrest 
ING4  1  Cell cycle arrest 
RB1  2  Negative regulation of cell cycle 
STK4 1  Pro-Apoptosis 
TSPYL2 1 Negative regulation of cell cycle 
miR-BHRF1-3   BCLL, BL, HG, L, LBCL, 
MCL 
BID 1  Pro-Apoptosis 
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Supplementary Table S2. Predicted targets for KSHV v-miRNAs. For each miRNA, the list of tissues where it is expressed, the 
predicted targets, the number of site on each target’s transcript and the GO term associated to the targets are shown. Tissues legend: 
BCBL: Body cavity-based lymphoma, BL: Burkitt’s lymphoma, PEL: Primary-effusion lymphoma. 
 
v-miRNA  Tissues  Target  Sites  Target’s GO terms 
miR-K12-1  BCBL, BL, PEL  FOXO3A  1  Pro-Apoptosis 
HBP1  1  Cell cycle arrest 
PDCD4  1  Negative regulation of cell cycle 
PCDC6  1  Negative regulation of cell cycle 
RBL1  1  Negative regulation of cell cycle 
RAD1  1  Cell cycle checkpoint 
TNFRSF10A 2  Pro-Apoptosis 
miR-K12-2  BCBL, BL, PEL  APC  2  Negative Regulation of cyclin-
dependent kinase activity 
CASP10a 1  Pro-Apoptosis 
CDKN2C  1  Cell cycle arrest 
CUL1  1  Cell cycle arrest 
CUL3 1  Pro-Apoptosis 
CUL5  1  Cell cycle arrest 
LATS2  1  Negative Regulation of cyclin-
dependent kinase activity 
MAPK1 1  Pro-Apoptosis 
RAD1  1  Cell cycle checkpoint 
RBBP8  1  Cell cycle checkpoint 
STK4 1  Pro-Apoptosis 
miR-K12-3  BCBL, BL, PEL  APBB1  1  Cell cycle arrest 
APC  1  Negative Regulation of cyclin-
dependent kinase activity 
CDKN2B  1  Cell cycle arrest 
CUL5  2  Cell cycle arrest 
FAF1 1  Pro-Apoptosis 
RASSF1  1  Cell cycle arrest 
RBBP8  2  Cell cycle checkpoint 
SMAD3  2  Cell cycle arrest 
STK3 1  Pro-Apoptosis 
STK4 3  Pro-Apoptosis 
miR-K12-4-5p  BCBL, BL, PEL  CCNG2  1  Cell cycle checkpoint 
ING1  1  Negative regulation of cell cycle 
RBL1  1  Negative regulation of cell cycle 
ZAK  1  Cell cycle arrest 
miR-K12-6-3p  BCBL, BL, PEL  BID  1  Pro-Apoptosis 
BTG3  1  Negative Regulation of mitotic 
cell cycle 
TBRG1  1  Cell cycle arrest 
miR-K12-7 PEL  ABL1  1  Pro-Apoptosis 
miR-K12-9  PEL  FOXO4  1  Cell cycle arrest 
TBRG1  1  Cell cycle arrest 
miR-K12-9*  BCBL, BL, PEL  CASP8a  1  Pro-Apoptosis 
TP53  1  Regulation of cell cycle 
miR-K12-10a  BCBL, BL, PEL  CASP10a 1  Pro-Apoptosis 
CASP10d 1  Pro-Apoptosis 
CUL2  2  Cell cycle arrest 
CUL4a  1  Cell cycle arrest 
EI24 1  Pro-Apoptosis 
FOXO4  1  Cell cycle arrest 
SMAD3  1  Cell cycle arrest 
miR-K12-10b  PEL  GAS7  1  Cell cycle arrest 
miR-K12-11 BL  BCL10  1  Pro-Apoptosis 
RB1  1  Negative regulation of cell cycle 
RBL1  1  Negative regulation of cell cycle 
APC  3  Negative Regulation of cyclin-
dependent kinase activity 
MPHOSPH1  1  Cell cycle arrest 
miR-K12-12 PEL  CASP10a  1  Pro-Apoptosis 
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Supplementary Table S3. Expression profiles of the predicted targets in infected cells. The profiles were retrieved from the NCBI 
GEO Profiles database. For each target, the GEO record ID, the virus, the mean value in the control sample (not infected), the mean 
value in the infected cell and the infected/control ratio are shown. Only values less than 1 are reported, since they indicate that the 
gene is under-expressed in the infected sample, compared to the control cell. 
 
Gene  GEO Record  Virus  Mean (Control)  Mean (Infected)  Ratio (I/C) 
ABL1  GDS989 - 1636_g_at   EBV  5928.75  3531.80  0.59 
GDS989 - 39730_at   EBV  5839.95  3504.20  0.60 
GDS989 - 1635_at  EBV  2786.60  1428.30  0.51 
GDS940 - 202123_s_at   KSHV  406.35  246.35  0,60 
APC  GDS940 - 203525_s_at   KSHV  110.60  63.90  0.57 
BCL10  GDS940 - 205263_at  KSHV  637.50 439.55  0.68 
BID  GDS940 - 204493_at   KSHV  263.25  140.40  0.53 
BTG3  GDS940 - 213134_x_at  KSHV 471.05  233.25  0.49 
CCNG2  GDS989 - 1913_at  EBV  2690.40  1679.80  0.62 
GDS940 - 211559_s_at  KSHV  109.65  98.55  0.89 
CDKN2C  GDS940 - 204159_at  KSHV  116.10  68.95  0.59 
CUL1  GDS940 - 207614_s_at  KSHV  266.50  214.25  0.80 
CUL2  GDS989 - 37894_at  EBV  817.95  454.50  0.55 
GDS940 - 203079_s_at  KSHV  254.00  164.40  0.64 
CUL3  GDS940 - 201371_s_at  KSHV  766.05  533.75  0.69 
CUL4A  GDS940 - 201423_s_at  KSHV  270.50  208.75  0.77 
CUL5  GDS940 - 203531_at  KSHV  323.30  256.55  0.79 
EI24  GDS940 - 216396_s_at  KSHV  349.60  202.05  0.57 
FAF1  GDS940 - 218080_x_at  KSHV  205.95  123.65  0.60 
FOXO3A  GDS940 - 204132_s_at /  KSHV  62.15  55.60  0.89 
HBP1  GDS940 - 209102_s_at  KSHV  281.35  274.65  0.97 
ING1  GDS940 - 209808_x_at  KSHV  73.90  61.05  0.82 
MAPK1  GDS989 - 976_s_at  EBV  1619.10  898.90  0.55 
GDS940 - 212271_at  KSHV  750.10  399.50  0.53 
MPHOSPH1  GDS940 - 205235_s_at  KSHV 120.15  54.95  0.45 
RAD1  GDS989 - 36857_at   EBV  2365.45  1954.6  0.82 
GDS940 - 204461_x_at   KSHV  176.50  77.55  0.43 
GDS940 - 204460_s_at  KSHV  136.75  73.85  0.54 
GDS940 - 210216_x_at  KSHV  158.55  102.85  0.64 
RASSF1  GDS940 - 204346_s_at  KSHV 116.65  73.90  0.63 
RB1  GDS989 - 2044_s_at  EBV  1307.35  1149.60  0.87 
GDS940 - 203132_at  KSHV  157.80  140.90  0.89 
GDS940 - 211540_s_at  KSHV  50.60  44.70  0.88 
RBBP8  GDS940 - 203344_s_at  KSHV  200.60  112.40  0.56 
SMAD3  GDS940 - 205398_s_at   KSHV  314.75  157.80  0.50 
STK3  GDS940 / 208855_s_at  KSHV  933.70  642.40  0.68 
STK4  GDS940 - 211085_s_at  KSHV  19.65  12.10  0.61 
TP53  GDS989 - 1974_s_at  EBV  1712.40  1561.70  0.91 
GDS989 - 1974_s_at  KSHV  1712.40  1530.25  0.89 
GDS940 - 201746_s_at  KSHV  405.70  370.00  0.91 
ZAK  GDS940 - 218833_at   KSHV  42.50  30.25  0.71 
 
 
 